Jonathan Wolleben
Stock Analyst at JMP Securities
(3.89)
# 718
Out of 4,412 analysts
125
Total ratings
38.35%
Success rate
12.96%
Average return
Main Sectors:
Top Industries:
20 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SVRA Savara | Reiterates: Market Outperform | $8 | $4.41 | +81.41% | 3 | Apr 19, 2024 | |
| RLYB Rallybio | Reiterates: Market Outperform | $8 | $1.70 | +370.59% | 11 | Apr 19, 2024 | |
| OCUL Ocular Therapeutix | Reiterates: Market Outperform | $24 | $4.75 | +405.80% | 13 | Apr 16, 2024 | |
| PHVS Pharvaris | Maintains: Market Outperform | $49 → $50 | $23.35 | +114.13% | 9 | Apr 11, 2024 | |
| CRNX Crinetics Pharmaceuticals | Reiterates: Market Outperform | $80 | $42.12 | +89.93% | 9 | Mar 28, 2024 | |
| LRMR Larimar Therapeutics | Reiterates: Market Outperform | $25 | $6.44 | +288.20% | 9 | Mar 15, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | n/a | $193.33 | - | 7 | Mar 15, 2024 | |
| SPRB Spruce Biosciences | Maintains: Market Outperform | $8 → $3 | $0.70 | +328.57% | 6 | Mar 14, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $69 → $72 | $24.46 | +194.36% | 6 | Mar 14, 2024 | |
| CLSD Clearside Biomedical | Reiterates: Market Outperform | $5 | $1.34 | +273.13% | 8 | Mar 13, 2024 | |
| PTGX Protagonist Therapeutics | Reiterates: Market Outperform | $42 | $25.15 | +67.00% | 6 | Mar 11, 2024 | |
| GPCR Structure Therapeutics | Reiterates: Market Outperform | $91 | $38.94 | +133.69% | 4 | Mar 8, 2024 | |
| SGMT Sagimet Biosciences | Maintains: Market Outperform | $47 → $46 | $4.06 | +1,033.00% | 5 | Feb 7, 2024 | |
| ALLK Allakos | Maintains: Market Outperform | $10 → $3 | $1.02 | +194.12% | 4 | Jan 17, 2024 | |
| AURA Aura Biosciences | Maintains: Market Outperform | $21 → $19 | $7.22 | +163.16% | 4 | Nov 10, 2023 | |
| DBVT DBV Technologies | Reiterates: Market Outperform | $4 | $0.68 | +486.51% | 7 | Aug 1, 2023 | |
| ALT Altimmune | Reiterates: Market Outperform | $15 | $7.26 | +106.61% | 8 | Jul 12, 2023 | |
| PRQR ProQR Therapeutics | Reiterates: Market Outperform | $6 | $1.94 | +209.28% | 4 | May 17, 2023 | |
| WMG Warner Music Group | Maintains: Outperform | $25 → $24 | $32.40 | -25.93% | 1 | May 12, 2023 | |
| BCRX BioCryst Pharmaceuticals | Reiterates: Market Outperform | $16 | $4.16 | +284.62% | 1 | Feb 22, 2023 |
Savara
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $4.41
Upside: +81.41%
Rallybio
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $1.70
Upside: +370.59%
Ocular Therapeutix
Apr 16, 2024
Reiterates: Market Outperform
Price Target: $24
Current: $4.75
Upside: +405.80%
Pharvaris
Apr 11, 2024
Maintains: Market Outperform
Price Target: $49 → $50
Current: $23.35
Upside: +114.13%
Crinetics Pharmaceuticals
Mar 28, 2024
Reiterates: Market Outperform
Price Target: $80
Current: $42.12
Upside: +89.93%
Larimar Therapeutics
Mar 15, 2024
Reiterates: Market Outperform
Price Target: $25
Current: $6.44
Upside: +288.20%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: n/a
Current: $193.33
Upside: -
Spruce Biosciences
Mar 14, 2024
Maintains: Market Outperform
Price Target: $8 → $3
Current: $0.70
Upside: +328.57%
Mirum Pharmaceuticals
Mar 14, 2024
Maintains: Outperform
Price Target: $69 → $72
Current: $24.46
Upside: +194.36%
Clearside Biomedical
Mar 13, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $1.34
Upside: +273.13%
Protagonist Therapeutics
Mar 11, 2024
Reiterates: Market Outperform
Price Target: $42
Current: $25.15
Upside: +67.00%
Structure Therapeutics
Mar 8, 2024
Reiterates: Market Outperform
Price Target: $91
Current: $38.94
Upside: +133.69%
Sagimet Biosciences
Feb 7, 2024
Maintains: Market Outperform
Price Target: $47 → $46
Current: $4.06
Upside: +1,033.00%
Allakos
Jan 17, 2024
Maintains: Market Outperform
Price Target: $10 → $3
Current: $1.02
Upside: +194.12%
Aura Biosciences
Nov 10, 2023
Maintains: Market Outperform
Price Target: $21 → $19
Current: $7.22
Upside: +163.16%
DBV Technologies
Aug 1, 2023
Reiterates: Market Outperform
Price Target: $4
Current: $0.68
Upside: +486.51%
Altimmune
Jul 12, 2023
Reiterates: Market Outperform
Price Target: $15
Current: $7.26
Upside: +106.61%
ProQR Therapeutics
May 17, 2023
Reiterates: Market Outperform
Price Target: $6
Current: $1.94
Upside: +209.28%
Warner Music Group
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $32.40
Upside: -25.93%
BioCryst Pharmaceuticals
Feb 22, 2023
Reiterates: Market Outperform
Price Target: $16
Current: $4.16
Upside: +284.62%